In May, there were two prominent acquisitions that centered on liquid biopsy technology. Labcorp agreed to pay $150m in cash for Myriad Genetics, Inc.’s autoimmune business; while NeoGenomics, Inc. acquired liquid biopsy company Inivata Ltd. for $390m to expand its growing cancer testing capabilities.
Labcorp has expanded its rheumatoid arthritis diagnostics line-up by acquiring the Vectra rheumatoid arthritis assay from Myriad Genetics. Myriad is...